Last reviewed · How we verify

SER120 Nasal Spray 500 ng/day — Competitive Intelligence Brief

SER120 Nasal Spray 500 ng/day (SER120 Nasal Spray 500 ng/day) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 3 Small molecule Live · refreshed every 30 min

Target snapshot

SER120 Nasal Spray 500 ng/day (SER120 Nasal Spray 500 ng/day) — Serenity Pharmaceuticals, Inc.. SER120 is an investigational nasal spray formulation with an unknown mechanism of action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SER120 Nasal Spray 500 ng/day TARGET SER120 Nasal Spray 500 ng/day Serenity Pharmaceuticals, Inc. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SER120 Nasal Spray 500 ng/day — Competitive Intelligence Brief. https://druglandscape.com/ci/ser120-nasal-spray-500-ng-day. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: